For Research Purposes Only
Tirzepatide — research peptide vial, third-party tested

Tirzepatide

From AED 1,450.00

Tirzepatide (LY3298176) is a synthetic dual agonist at the GIP and GLP-1 receptors, supplied as a pre-loaded multi-dose injector pen for research and laboratory use only.

With a molecular weight of approximately 4,813 g/mol, it is among the most extensively studied compounds in metabolic research — including the SURMOUNT-1 trial published in the New England Journal of Medicine. Published pharmacology attributes its distinct profile to combined activity at both incretin receptors rather than GLP-1 signalling alone.

Every batch is HPLC-verified by an independent laboratory. Certificates of Analysis are published on the product page as each batch is verified — ask us if you need the report for a specific batch. Store at 2–8 °C in the dark.

Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease.

1
Next-day deliveryOrder today for delivery tomorrow across the UAE
Free Shipping
Secure Checkout
Free Shipping
Secure Checkout
Share:

Shipping & Returns

FAQ

Dosing Chart

Frequently Bought Together

+
+
This itemAED 1,450.00
RetatrutideAED 1,450.00
NAD+AED 950.00
Bundle price:AED 3,850.00
Verification

Every batch is tested by an independent lab

Tirzepatide is analysed by HPLC through Janoshik Analytical — an independent laboratory, not our own. Certificates of Analysis are published on the product page as each batch is verified — this one is still being processed. If you need the report for a specific batch before ordering, ask us and we will get it to you.

  • Independently assayed

    HPLC analysis by a third-party lab, per batch.

  • Batch-traceable

    The COA identifies the specific batch you receive.

  • Available on request

    Ask us for the report on a specific batch.

Need the batch documentation before you order? Ask us for it · Research use only

Why it matters.

01

Dual-agonist peptide.

One molecule, two incretin receptors. GIP and GLP-1.

02

Verified by Janoshik.

Independent HPLC + MS testing. Report linked above.

03

Reference-grade.

Lyophilised powder. Sealed, labelled, batch-traceable.

How it works

Three receptors. One molecule.

01 / 03

GLP-1 receptor

Studied for glucose-dependent insulin secretion and gastric emptying.

02 / 03

GIP receptor

Glucose-dependent insulinotropic polypeptide receptor, studied for lipid handling and insulin response.

03 / 03

Incretin synergy

GIP and GLP-1 co-agonism studied for greater metabolic effect than GLP-1 alone.

Reference data

Inside the pen.

The molecular profile, confirmed by independent analysis.

CompoundTirzepatide (LY3298176)
ClassDual GIP / GLP-1 receptor agonist
Molecular weight≈ 4,813 g/mol
FormMulti-dose injector pen
UseResearch and laboratory use only
Storage2–8 °C, dark
Tools

Dosing & reconstitution calculator

Enter your own values to work out concentration, volume and clicks. A calculation tool only — not dosing guidance.

Target dose
Clicks per dose1
Volume per dose0.013 ml
Doses per pen240
Concentration20 mg/ml
Per click0.25 mg
Pen total60 mg

For research and laboratory use only. This tool performs arithmetic on the values you enter and does not constitute dosing, medical, or veterinary advice. Always verify calculations independently.

Sources

Cited, not claimed.

Every reference below is publicly available, peer-reviewed.

012220
NEJM · SURMOUNT-1

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM et al. · New England Journal of Medicine

FAQ's

What is Tirzepatide?

How does a dual GIP/GLP-1 agonist differ from a GLP-1 agonist?

What research has been published on Tirzepatide?

How does Tirzepatide compare with Retatrutide?

Is this compound third-party tested?

What is a Certificate of Analysis, and why does it matter?

How should Tirzepatide be stored?

Is this product intended for human use?

How quickly is it shipped?